Reliable drug information is the backbone of safe and effective patient care. It's what helps make informed decisions, optimize therapeutic outcomes, and confidently navigate the complex healthcare landscape. For early-career professionals, knowing where to find trusted, evidence-based resources - like drug databases and clinical decision-support tools - can be a real game-changer.

Crohn's disease and ulcerative colitis are chronic autoimmune disorders associated with major clinical and economic burden. The American College of Gastroenterology (ACG) recently released updates to their clinical guidelines for the Management of Crohn's Disease (CD) and Ulcerative Colitis (UC) in Adults. Both guidelines incorporate available evidence to provide recommendations for the treatment and prevention of complications associated with inflammatory bowel disease (IBD). The objective of this webinar is to highlight guideline updates and provide suggestions for application of the recommendations into practice and payer policy.

IgA nephropathy is an autoimmune, progressive, chronic kidney disease characterized by pathogenic IgA accumulation and immune complex formation in the glomerulus, causing inflammation and progressive kidney damage. The webinar will review IgA nephropathy and clinical outcomes from Phase 2 and 3 trials of an investigational product that is under clinical evaluation for the treatment of primary IgA nephropathy in adults. Efficacy and safety have not yet been established.

Advance understanding of the importance of frequent monitoring risk level of pulmonary arterial hypertension (PAH) and right heart monitoring. Explore and discuss the importance of timely escalation of therapies in the treatment of PAH. Participants will learn about the significant role risk stratification plays in informing providers' treatment decisions, as well as the importance of right heart and hemodynamic considerations in conjunction with risk assessment.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

This webinar highlights an introduction to Scholar Rock, an emerging biopharmaceutical company, and provides an overview of the Spinal Muscular Atrophy (SMA) disease landscape, remaining unmet needs in SMA, and apitegromab clinical data.

Pre-Approval Information Exchange presentation for investigational revumenib, including a clinical overview, burden of disease, and disease background for pediatric and adult patients with NPM1-mutated relapsed or refractory acute myeloid leukemia.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Join the inaugural event of AMCP’s AI LINK Interest Group and explore how artificial intelligence is transforming managed care pharmacy. We’ll dive into why standardized frameworks are essential to evaluate AI-driven solutions and how transparent, interoperable tools can help payors make informed, safe, and efficient coverage decisions. Not in an AMCP LINK yet? AMCP members can sign up now. 

Guest Experts: 

• Brenton Hill, JD, MHA - CHAI 
• Keith Kallmes - Knested Knowledge 
• Adam Colborn, JD - AMCP